FDA clearance for the next-generation version of the company’s wearable insulin delivery pump system covers individuals aged 6 years and older with type 1 diabetes. The platform provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks.
Get the full story at our sister site, Drug Delivery Business News.